vs
美国运通（AXP）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是美国运通的1.0倍（$19.6M vs $18.9M），美国运通净利率更高（15.7% vs -177.4%，领先193.1%），美国运通同比增速更快（11.4% vs -11.5%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -95.6%）
美国运通是全球知名的支付服务提供商，主营签账卡、信用卡产品及旅行相关服务，下设全球消费者服务、全球商业服务、全球商户与网络服务三大业务板块，还提供支付融资、网络服务、应付账款费用管理、旅行生活服务等多元解决方案。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
AXP vs LAB — 直观对比
营收规模更大
LAB
是对方的1.0倍
$18.9M
营收增速更快
AXP
高出22.9%
-11.5%
净利率更高
AXP
高出193.1%
-177.4%
两年增速更快
LAB
近两年复合增速
-95.6%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $19.6M |
| 净利润 | $3.0M | $-34.7M |
| 毛利率 | — | 48.5% |
| 营业利润率 | — | -168.5% |
| 净利率 | 15.7% | -177.4% |
| 营收同比 | 11.4% | -11.5% |
| 净利润同比 | 15.0% | -28.8% |
| 每股收益（稀释后） | — | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AXPLAB
| Q1 26 | $18.9M | — | ||
| Q4 25 | $10.9B | — | ||
| Q3 25 | $10.4B | $19.6M | ||
| Q2 25 | $10.3B | $21.8M | ||
| Q1 25 | $9.6B | $40.8M | ||
| Q4 24 | $10.0B | — | ||
| Q3 24 | $9.7B | $22.1M | ||
| Q2 24 | $9.8B | $22.5M |
净利润AXPLAB
| Q1 26 | $3.0M | — | ||
| Q4 25 | $2.5B | — | ||
| Q3 25 | $2.9B | $-34.7M | ||
| Q2 25 | $2.9B | $-33.5M | ||
| Q1 25 | $2.6B | $-26.0M | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.5B | $-26.9M | ||
| Q2 24 | $3.0B | $-45.7M |
毛利率AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 48.5% | ||
| Q2 25 | — | 48.8% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | — | 46.1% |
营业利润率AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | 28.2% | — | ||
| Q3 25 | 36.7% | -168.5% | ||
| Q2 25 | 34.4% | -118.1% | ||
| Q1 25 | 34.6% | -80.8% | ||
| Q4 24 | 27.7% | — | ||
| Q3 24 | 33.0% | -120.9% | ||
| Q2 24 | 38.6% | -134.5% |
净利率AXPLAB
| Q1 26 | 15.7% | — | ||
| Q4 25 | 22.5% | — | ||
| Q3 25 | 27.9% | -177.4% | ||
| Q2 25 | 28.0% | -153.7% | ||
| Q1 25 | 26.8% | -63.8% | ||
| Q4 24 | 21.8% | — | ||
| Q3 24 | 25.8% | -122.0% | ||
| Q2 24 | 30.7% | -203.3% |
每股收益（稀释后）AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | $3.52 | — | ||
| Q3 25 | $4.14 | $-0.09 | ||
| Q2 25 | $4.08 | $-0.09 | ||
| Q1 25 | $3.64 | $-0.07 | ||
| Q4 24 | $3.04 | — | ||
| Q3 24 | $3.49 | $-0.07 | ||
| Q2 24 | $4.15 | $-0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $129.4M |
| 总债务越低越好 | $60.4M | — |
| 股东权益账面价值 | $34.0M | $399.7M |
| 总资产 | $308.9M | $539.6M |
| 负债/权益比越低杠杆越低 | 1.78× | — |
8季度趋势，按日历期对齐
现金及短期投资AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | $742.0M | — | ||
| Q3 25 | $1.3B | $129.4M | ||
| Q2 25 | $197.0M | $158.6M | ||
| Q1 25 | $261.0M | $150.9M | ||
| Q4 24 | $221.0M | — | ||
| Q3 24 | $120.0M | $210.6M | ||
| Q2 24 | $188.0M | $269.8M |
总债务AXPLAB
| Q1 26 | $60.4M | — | ||
| Q4 25 | $56.4B | — | ||
| Q3 25 | $57.8B | — | ||
| Q2 25 | $58.2B | — | ||
| Q1 25 | $51.2B | — | ||
| Q4 24 | $49.7B | — | ||
| Q3 24 | $53.5B | $55.2M | ||
| Q2 24 | $51.5B | $55.1M |
股东权益AXPLAB
| Q1 26 | $34.0M | — | ||
| Q4 25 | $33.5B | — | ||
| Q3 25 | $32.4B | $399.7M | ||
| Q2 25 | $32.3B | $424.5M | ||
| Q1 25 | $31.2B | $454.6M | ||
| Q4 24 | $30.3B | — | ||
| Q3 24 | $29.7B | $489.3M | ||
| Q2 24 | $29.5B | $510.3M |
总资产AXPLAB
| Q1 26 | $308.9M | — | ||
| Q4 25 | $300.1B | — | ||
| Q3 25 | $297.6B | $539.6M | ||
| Q2 25 | $295.6B | $557.0M | ||
| Q1 25 | $282.2B | $579.6M | ||
| Q4 24 | $271.5B | — | ||
| Q3 24 | $271.0B | $681.5M | ||
| Q2 24 | $272.2B | $708.7M |
负债/权益比AXPLAB
| Q1 26 | 1.78× | — | ||
| Q4 25 | 1.68× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 1.80× | — | ||
| Q1 25 | 1.64× | — | ||
| Q4 24 | 1.64× | — | ||
| Q3 24 | 1.80× | 0.11× | ||
| Q2 24 | 1.74× | 0.11× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | — | $-23.1M |
| 自由现金流率自由现金流/营收 | — | -118.1% |
| 资本支出强度资本支出/营收 | — | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | $3.1B | — | ||
| Q3 25 | $6.2B | $-22.2M | ||
| Q2 25 | $4.4B | $-20.7M | ||
| Q1 25 | $4.8B | $-30.3M | ||
| Q4 24 | $5.8B | — | ||
| Q3 24 | $-1.8B | $-27.9M | ||
| Q2 24 | $4.5B | $-39.0M |
自由现金流AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | $2.3B | — | ||
| Q3 25 | $5.6B | $-23.1M | ||
| Q2 25 | $3.7B | $-22.6M | ||
| Q1 25 | $4.3B | $-35.3M | ||
| Q4 24 | $5.3B | — | ||
| Q3 24 | $-2.3B | $-30.1M | ||
| Q2 24 | $4.0B | $-41.0M |
自由现金流率AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | 21.4% | — | ||
| Q3 25 | 53.6% | -118.1% | ||
| Q2 25 | 36.3% | -103.6% | ||
| Q1 25 | 45.0% | -86.6% | ||
| Q4 24 | 53.1% | — | ||
| Q3 24 | -23.3% | -136.4% | ||
| Q2 24 | 40.4% | -182.2% |
资本支出强度AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | 6.6% | — | ||
| Q3 25 | 6.3% | 4.5% | ||
| Q2 25 | 6.0% | 8.7% | ||
| Q1 25 | 4.5% | 12.4% | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 4.7% | 10.2% | ||
| Q2 24 | 5.8% | 8.6% |
现金转化率AXPLAB
| Q1 26 | — | — | ||
| Q4 25 | 1.25× | — | ||
| Q3 25 | 2.15× | — | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 1.84× | — | ||
| Q4 24 | 2.66× | — | ||
| Q3 24 | -0.72× | — | ||
| Q2 24 | 1.50× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AXP
| Discount revenue | $9.5M | 50% |
| Other | $8.9M | 47% |
| Deposits with banks and other | $512.0K | 3% |
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
